A state research facility in Moscow – the Gamaleya Institute – completed early human trials of the adenovirus-based vaccine this month and expects to begin large-scale trials in August.
The vaccine will win regulatory approval from authorities in Russia while that large-scale trial continues, the source said, highlighting Moscow’s determination to be the first country in the world to approve a vaccine.
“(Regulatory) approval will be in the first two weeks of August,” the development source said. “August 10 is the expected date, but it will definitely be before August 15. All (trial) results so far are highly positive.”
The source added that Russian health workers treating COVID-19 patients will be offered the chance of volunteering to be vaccinated soon after the vaccine receives the regulatory approval.
Separately, Russia’s Interfax news agency cited “an informed source” as saying the vaccine would be registered from Aug. 10-12 and be administered from Aug. 15 onwards.
The press service of the Russian Direct Investment Fund (RDIF), which is coordinating and funding Russia’s vaccine development efforts, declined to comment, but its head, Kirill Dmitriev, has denied that Russia’s vaccine push is compromising safety.
“The Ministry of Health in Russia is following all necessary strict procedures. No corners are being cut,” Dmitriev said on Tuesday.Dmitriev likened what he said was Russia’s success in developing a vaccine to the Soviet Union’s 1957 launch of Sputnik 1, the world’s first satellite.
